A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system
Abstract
Aim: Characterize the pharmacokinetic profile and tolerability of two tocopheryl phosphate mixture/oxymorphone patch formulations in healthy subjects, and the active metabolite (6-OH-oxymorphone). Materials & methods: Fifteen participants received a single application of oxymorphone patches +/− capsaicin for 72 h and were crossed-over for another 72 h. Results: Plasma oxymorphone was detected approximately 7 h and 6-OH-oxymorphone after approximately 18–19 h postapplication of both formulations, respectively. For oxymorphone, median tmax was 24 h, and Cmax/Cmin ratio was approximately 2.4. The most frequently reported treatment-related adverse event was application site reaction, mainly with capsaicin formulation. Conclusion: Tocopheryl phosphate mixture/oxymorphone transdermal patches can successfully deliver therapeutic amounts of oxymorphone in a sustained manner over 72 h and are well tolerated.
ANZCTR registration number: ACTRN12614000613606
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10(2), 113–30 (2009).
- 2 . The doctor's dilemma: opiate analgesics and chronic pain. Neuron 69(4), 591–594 (2011).
- 3 Controlled-release of opioids for improved pain management. Mater. Today 19(9), 491–502 (2016). • Reviews current strategies for using opioids to manage acute and chronic pain indications.
- 4 . The usage of opioids and their adverse effects in gastrointestinal practice: a review. Middle East J. Dig. Dis. 5(1), 5–16 (2013). • Reviews the various adverse effects that result from oral opioid therapy.
- 5 A review of abuse-deterrent opioids for chronic nonmalignant pain. PT 37(7), 412–418 (2012).
- 6 . Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs. Am. Health Drug Benefits 4(2), 107–114 (2011).
- 7 FDA. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM492172.pdf.
- 8 . Update on prescription extended-release opioids and appropriate patient selection. J. Multidiscip. Healthc. 6, 265–280 (2013).
- 9 . Transdermal drug delivery: principles and opioid therapy, continuing education in anaesthesia. Crit. Care Pain 7(5), 171–176 (2007).
- 10 . The effect of food intake on the pharmacokinetics of sustained-release morphine sulfate capsules. Clin. Ther. 19(2), 296–303 (1997).
- 11 . Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage 19, 930–938 (2011).
- 12 . Transdermal drug delivery in pain management. Contin. Educ. Anaesth. Crit. Care Pain 11(2), 39–43 (2011). • Provides a review of various transdermal options for the management of pain.
- 13 . Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. J. Pain Res. 8, 859–70 (2015).
- 14 . A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr. Med. Res. Opin. 22, 501–509 (2006).
- 15 . Assessment of transdermal buprenorphine patches for the treatment of chronic pain in a UK observational study. Patient 9(1), 35–46 (2016).
- 16 BuTrans patches – Summary of Product Characteristics. https://www.medicines .org.uk/emc/medicine/16787
- 17 . Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive and placebo-controlled trials. Postgrad. Med. 129(1), 69–80 (2017).
- 18 . Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches. CMAJ 188(9), 648–653 (2016).
- 19 . Pharmacokinetics, safety and tolerability of a novel TPM/oxycodone transdermal patch system: a Phase I study. Pain Manag.
doi:10.2217/pmt-2016-0068 (2017) (Epub ahead of print). •• Describes results from a Phase I clinical trial examining the transdermal delivery of oxycodone from a tocopheryl phosphate mixture matrix patch. - 20 . Tocopheryl phosphate mixture (TPM) as a novel lipid-based transdermal drug delivery carrier: formulation and evaluation. Drug Deliv. Transl. Res. 7(1), 53–65 (2017). •• Provides a review and summary of the physicochemical characteristics and morphological properties of tocopheryl phosphate mixture formulations.
- 21 . Clinical pharmacology of oxymorphone. Pain Med. 10(s1), S3–S10 (2009). •• Describes the pharmacology, metabolism and adverse effects associated with oxymorphone.
- 22 . Opioid pharmacology. Pain Physician 11(Suppl. 2), S133–S153 (2008).
- 23 OPANA®. (Oxymorphone hydrochloride) tablets [prescribing information]. Endo Pharamceuticals, Inc., PA, USA (2012). www.accessdata.fda.gov/drugsatfda_docs/label/2012/021611s007lbl.pdf.
- 24 OPANA®. ER (oxymorphone hydrochloride) Extended-Release tablets [prescribing information]. Endo Pharamceuticals Inc., PA, USA (2016). www.endo.com/File%20Library/Products/Prescribing%20Information/OpanaER_prescribing_information_newformulation.html.
- 25 Medscape Medical News. www.medscape.com/viewarticle/877352.
- 26 . Transdermal buprenorphine in the management of persistent pain – safety aspects. Ther. Clin. Risk Manag. 2(1), 115–125 (2006).
- 27 . A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 90(2), 576–599 (1999).
- 28 . Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial. Pain Manag.
doi:10.2217/pmt-2016-0067 (2017) (Epub ahead of print). - 29 . The actions of capsaicin applied topically to the skin of the rat on C-fibre afferents, antidromic vasodilatation and substance P levels. Br. J. Pharmacol. 107(2), 400–406 (1992).
- 30 . Capsaicin 8% topical patch (Qutenza) – a review of the evidence. J. Pain Palliat. Care Pharmacother. 25(1), 32–41 (2011).
- 31 . Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Clin. Ther. 29(8), 1591–1606 (2007).
- 32 Allergic contact dermatitis due to transdermal buprenorphine. Contact Dermatitis 58(5), 310–312 (2008).
- 33 US FDA. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm.
- 34 Medline Plus. https://medlineplus.gov/news/fullstory_166423.html.